Schwab Charles Investment Management Inc. increased its stake in Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 8.5% during the second quarter, according to its most recent filing with the SEC. The fund owned 989,006 shares of the biopharmaceutical company’s stock after buying an additional 77,388 shares during the quarter. Schwab Charles Investment Management Inc. owned 0.52% of Amicus Therapeutics worth $15,449,000 at the end of the most recent quarter.
Several other large investors also recently modified their holdings of the stock. Quantitative Systematic Strategies LLC purchased a new position in shares of Amicus Therapeutics in the 2nd quarter worth about $179,000. Rothschild Asset Management Inc. lifted its holdings in Amicus Therapeutics by 145.0% during the second quarter. Rothschild Asset Management Inc. now owns 235,513 shares of the biopharmaceutical company’s stock valued at $3,679,000 after purchasing an additional 139,382 shares during the last quarter. Strs Ohio lifted its holdings in Amicus Therapeutics by 32.2% during the second quarter. Strs Ohio now owns 16,000 shares of the biopharmaceutical company’s stock valued at $249,000 after purchasing an additional 3,900 shares during the last quarter. Bank of New York Mellon Corp lifted its holdings in Amicus Therapeutics by 0.3% during the second quarter. Bank of New York Mellon Corp now owns 2,046,768 shares of the biopharmaceutical company’s stock valued at $31,970,000 after purchasing an additional 6,931 shares during the last quarter. Finally, Rhumbline Advisers lifted its holdings in Amicus Therapeutics by 5.9% during the second quarter. Rhumbline Advisers now owns 183,812 shares of the biopharmaceutical company’s stock valued at $2,871,000 after purchasing an additional 10,306 shares during the last quarter.
In related news, major shareholder Perceptive Advisors Llc purchased 20,000 shares of the firm’s stock in a transaction dated Monday, September 24th. The shares were purchased at an average cost of $12.45 per share, for a total transaction of $249,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, major shareholder Life Sciences Maste Perceptive purchased 50,000 shares of the firm’s stock in a transaction dated Friday, September 21st. The shares were bought at an average price of $12.53 per share, for a total transaction of $626,500.00. The disclosure for this purchase can be found here. Over the last quarter, insiders have bought 620,000 shares of company stock worth $7,505,000. Company insiders own 2.90% of the company’s stock.
NASDAQ FOLD opened at $13.24 on Tuesday. Amicus Therapeutics, Inc. has a 52 week low of $11.57 and a 52 week high of $17.62. The stock has a market cap of $2.29 billion, a price-to-earnings ratio of -4.53 and a beta of 1.33. The company has a current ratio of 10.88, a quick ratio of 10.73 and a debt-to-equity ratio of 0.30.
Amicus Therapeutics (NASDAQ:FOLD) last announced its quarterly earnings results on Tuesday, August 7th. The biopharmaceutical company reported ($0.33) earnings per share for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.33). Amicus Therapeutics had a negative return on equity of 53.45% and a negative net margin of 460.04%. The firm had revenue of $21.31 million for the quarter, compared to analysts’ expectations of $18.92 million. On average, analysts anticipate that Amicus Therapeutics, Inc. will post -1.19 earnings per share for the current fiscal year.
About Amicus Therapeutics
Amicus Therapeutics, Inc, a biotechnology company, engages in the discovery, development, and commercialization of medicines for various rare and orphan diseases. The company offers migalastat HCl, an orally administered small molecule pharmacological chaperone for the treatment of Fabry disease. It is also conducting a Phase 1/2 clinical study of ATB200-02 to investigate in patients with pompe disease.
Featured Story: Google Finance Portfolio
Receive News & Ratings for Amicus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.